It is exciting to be on the forefront of peptide and cellular medicine and to see how peptides will be integrated into the future of medicine
Samples were tested for the presence of AIs (2-androstenol (5-androst-2-en-17-ol), 2-androstenone (5-androst-2-en-17-one), 3-androstenol (5-androst-3-en-17-ol), 3-androstenone (5-androst-3-en-17-one), 4-androstene-3,6,17 trione (6-oxo), aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), androsta-3,5-diene-7,17-dione (arimistane), exemestane, formestane, letrozole, and testolactone), and anti-estrogenic substance (bazedoxifene, clomiphene, cyclofenil, fulvestrant, ospemifene, raloxifene, tamoxifen, and toremifene) prohibited by WADA
result review pending BPC-157 10MG research batch with 10MG, research-use compound, current lot visibility, and direct certificate access
Disclosure of interest: Ian Johnson: nothing to disclose
10 BPC-157 has demonstrated significant angiogenic effects in various healing models
